Stockscreener 앱 받기
540.05
0.84%
-4.57
시장 영업 전:
540.91
0.86
+0.16%
전일 마감가:
$544.62
열려 있는:
$537.56
하루 거래량:
423.80K
Relative Volume:
0.81
시가총액:
$22.92B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
19.93
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
-6.64%
1개월 성능:
-5.32%
6개월 성능:
+13.90%
1년 성능:
+65.92%
1일 변동 폭
$534.97
$544.91
1주일 범위
$534.97
$580.39
52주 변동 폭
$272.12
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
540.05 | 23.12B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 48.00B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.08 | 40.34B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.70 | 39.10B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.39 | 32.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics CFO James Edgemond sells $5.48m in shares - Investing.com
United Therapeutics CEO Martine Rothblatt sells $5.2m in company stock - Investing.com
United Therapeutics CEO Rothblatt sells $863,947 in stock By Investing.com - Investing.com India
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring a 19.47% Potential Upside - DirectorsTalk Interviews
United Therapeutics Corporation (UTHR): Renaissance Technologies Likes This Biotech Stock - Insider Monkey
United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock - Investing.com UK
United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock By Investing.com - Investing.com South Africa
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
United Therapeutics Corporation (UTHR) Latest Stock News & Headlines - Yahoo Finance
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
United Therapeutics Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares - Investing.com India
United Therapeutics CEO Martine Rothblatt sells $5.38m UTHR shares By Investing.com - Investing.com India
United Therapeutics CEO Rothblatt sells $5.4m in common stock By Investing.com - Investing.com India
United Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation Lags - Yahoo Finance
United Therapeutics stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.4m in common stock - Investing.com
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
United Therapeutics (UTHR) Remains a Key Holding for Renaissance Technologies - GuruFocus
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock - Investing.com Nigeria
United Therapeutics (UTHR) Reports TETON Study Results on Nebuli - GuruFocus
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock By Investing.com - Investing.com South Africa
United Therapeutics’ Tyvaso meets primary endpoint in IPF trial - Investing.com
Inhaled Tyvaso preserves lung function, cuts IPF risks in trial - Stock Titan
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics (UTHR) Reports Positive Ralinepag Results in Pulmonary Hypertension Study - GuruFocus
Baidu, Brady And 3 Stocks To Watch Heading Into Monday - Benzinga
Experimental PAH pill ralinepag cuts worsening risk 55% in Phase 3 - Stock Titan
Leuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock (US9113631090): FDA clears first UHeart xenotransplantation trial - AD HOC NEWS
United Therapeutics Corporation $UTHR Stock Position Decreased by Thrivent Financial for Lutherans - MarketBeat
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call - Yahoo Finance
United Therapeutics Corporation Announces Fda Clearance to Proceed with Uheart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics stock (US9113631090): fresh data push at ATS 2026 keeps pipeline in focus - AD HOC NEWS
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
자본화:
|
볼륨(24시간):